Compound K is a potential clinical anticancer agent in prostate cancer by arresting cell cycle.
暂无分享,去创建一个
A. Zhang | Jihong Liu | Shaoyong Chen | Yu Deng | Weimin Yao | Xiaming Liu | Shaogang Wang | Man Liu | Yucong Zhang | Xintao Gao | Yi Wang | Jiaxin Wang
[1] Sung-Hoon Kim,et al. Inhibition of STAT3/PD-L1 and Activation of miR193a-5p Are Critically Involved in Apoptotic Effect of Compound K in Prostate Cancer Cells , 2021, Cells.
[2] Koustav Pal,et al. Prostate cancer: Therapeutic prospect with herbal medicine , 2021, Current research in pharmacology and drug discovery.
[3] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[4] Fen Ma,et al. Phosphorylation of the androgen receptor at Ser81 is co‐sustained by CDK1 and CDK9 and leads to AR‐mediated transactivation in prostate cancer , 2021, Molecular oncology.
[5] Jinyi Zhou,et al. Characterization of ginsenoside compound K loaded ionically cross-linked carboxymethyl chitosan–calcium nanoparticles and its cytotoxic potential against prostate cancer cells , 2020, Journal of ginseng research.
[6] Joshua M. Stuart,et al. Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer , 2020, Clinical Cancer Research.
[7] Anshul Sharma,et al. Ginsenoside Compound K: Insights into Recent Studies on Pharmacokinetics and Health-Promoting Activities , 2020, Biomolecules.
[8] Wei Zhang,et al. CARM1 promotes non-small cell lung cancer progression through upregulating CCNE2 expression , 2020, Aging.
[9] Yuzhuo Wang,et al. PKMYT1 is associated with prostate cancer malignancy and may serve as a therapeutic target. , 2020, Gene.
[10] Lei Wang,et al. Weighted gene co-expression network analysis identifies CCNA2 as a treatment target of prostate cancer through inhibiting cell cycle , 2020, Journal of Cancer.
[11] Eunhee Kim,et al. Ginsenoside Compound K Induces Ros-Mediated Apoptosis and Autophagic Inhibition in Human Neuroblastoma Cells In Vitro and In Vivo , 2019, International journal of molecular sciences.
[12] J. Kim,et al. AKT1-targeted proapoptotic activity of compound K in human breast cancer cells , 2019, Journal of ginseng research.
[13] Damian Szklarczyk,et al. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..
[14] H. Kim,et al. Compound K, a ginsenoside metabolite, plays an antiinflammatory role in macrophages by targeting the AKT1-mediated signaling pathway , 2018, Journal of ginseng research.
[15] Chen Li,et al. Ginsenoside metabolite compound K induces apoptosis and autophagy in non-small cell lung cancer cells via AMPK-mTOR and JNK pathways. , 2019, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[16] E. Winquist,et al. Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer , 2018, Expert opinion on emerging drugs.
[17] Yan Yan,et al. Compound K Induces Endoplasmic Reticulum Stress and Apoptosis in Human Liver Cancer Cells by Regulating STAT3 , 2018, Molecules.
[18] Yicheng Wang,et al. Single- and Multiple-Dose Trials to Determine the Pharmacokinetics, Safety, Tolerability, and Sex Effect of Oral Ginsenoside Compound K in Healthy Chinese Volunteers , 2018, Front. Pharmacol..
[19] Sang Yeol Lee. Synergistic effect of maclurin on ginsenoside compound K induced inhibition of the transcriptional expression of matrix metalloproteinase-1 in HaCaT human keratinocyte cells , 2017, Journal of ginseng research.
[20] J. Cho,et al. The skin protective effects of compound K, a metabolite of ginsenoside Rb1 from Panax ginseng , 2017, Journal of ginseng research.
[21] Huixia Lv,et al. Targeted delivery of ginsenoside compound K using TPGS/PEG-PCL mixed micelles for effective treatment of lung cancer , 2017, International journal of nanomedicine.
[22] ShaoChuang Wang,et al. PKMYT1 promoted the growth and motility of hepatocellular carcinoma cells by activating beta‐catenin/TCF signaling , 2017, Experimental cell research.
[23] S. Olesen,et al. Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors. , 2017, Journal of medicinal chemistry.
[24] Yicheng Wang,et al. Food and Sex-Related Impacts on the Pharmacokinetics of a Single-Dose of Ginsenoside Compound K in Healthy Subjects , 2017, Front. Pharmacol..
[25] J. Sohng,et al. The ginsenoside metabolite compound K inhibits growth, migration and stemness of glioblastoma cells , 2017, International journal of oncology.
[26] E. Steyerberg,et al. Value of cyclin A immunohistochemistry for cancer risk stratification in Barrett esophagus surveillance , 2016, Medicine.
[27] A. Jemal,et al. Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.
[28] Zhenhai Zhang,et al. Ginseng consumption and risk of cancer: A meta-analysis , 2015, Journal of ginseng research.
[29] Emily J. Girard,et al. Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells. , 2015, Cell reports.
[30] Xiaoxin Lan,et al. Ginsenoside Compound K suppresses the hepatic gluconeogenesis via activating adenosine-5'monophosphate kinase: A study in vitro and in vivo. , 2015, Life sciences.
[31] Xuekun Song,et al. CCNB2 overexpression is a poor prognostic biomarker in Chinese NSCLC patients. , 2015, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[32] N. Seki,et al. Tumour-suppressive microRNA-144-5p directly targets CCNE1/2 as potential prognostic markers in bladder cancer , 2015, British Journal of Cancer.
[33] Jian Zhang,et al. Ginsenoside metabolite compound K enhances the efficacy of cisplatin in lung cancer cells. , 2015, Journal of thoracic disease.
[34] Yi Pan,et al. CytoNCA: A cytoscape plugin for centrality analysis and evaluation of protein interaction networks , 2015, Biosyst..
[35] P. Kaldis,et al. Loss of Cdk2 and cyclin A2 impairs cell proliferation and tumorigenesis. , 2014, Cancer research.
[36] K. Kang,et al. Compound K, a metabolite of ginseng saponin, inhibits colorectal cancer cell growth and induces apoptosis through inhibition of histone deacetylase activity. , 2013, International journal of oncology.
[37] R. Poon,et al. The CDK1 inhibitory kinase MYT1 in DNA damage checkpoint recovery , 2013, Oncogene.
[38] Jihui Wang,et al. Compound K induces apoptosis of bladder cancer T24 cells via reactive oxygen species-mediated p38 MAPK pathway. , 2013, Cancer biotherapy & radiopharmaceuticals.
[39] N. Bhattacharyya,et al. MicroRNA-124 targets CCNA2 and regulates cell cycle in STHdh(Q111)/Hdh(Q111) cells. , 2013, Biochemical and biophysical research communications.
[40] M. Benkirane,et al. Phosphorylation of SAMHD1 by cyclin A2/CDK1 regulates its restriction activity toward HIV-1. , 2013, Cell reports.
[41] G. Bartsch,et al. The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line. , 2011, Cancer letters.
[42] B. Bao,et al. Activated K-ras and INK4a/Arf Deficiency Cooperate During the Development of Pancreatic Cancer by Activation of Notch and NF-κB Signaling Pathways , 2011, PloS one.
[43] P. C. de Witt Hamer,et al. WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe , 2011, Clinical Cancer Research.
[44] Hai-Meng Zhou,et al. Use of Serum Circulating Ccnb2 in Cancer Surveillance , 2010, The International journal of biological markers.
[45] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[46] Mark D. Robinson,et al. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..
[47] R. Sutherland,et al. Expression and prognostic significance of cyclin B1 and cyclin A in non‐small cell lung cancer , 2009, Histopathology.
[48] Brad T. Sherman,et al. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.
[49] G. Bubley,et al. Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1 , 2006, Proceedings of the National Academy of Sciences.
[50] S. Helms. Cancer prevention and therapeutics: Panax ginseng. , 2004, Alternative medicine review : a journal of clinical therapeutic.
[51] D. Korenaga,et al. Clinicopathologic significance of cyclin A expression in colorectal carcinoma. , 2004, Journal of experimental & clinical cancer research : CR.
[52] T. Yun. Experimental and epidemiological evidence on non-organ specific cancer preventive effect of Korean ginseng and identification of active compounds. , 2003, Mutation research.
[53] N. Rosen,et al. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. , 2000, Cancer research.
[54] R. Chetty,et al. Cyclin E in human cancers , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[55] K. Kobashi,et al. Drug Metabolism: Intestinal Bacterial Hydrolysis is Required for the Appearance of Compound K in Rat Plasma after Oral Administration of Ginsenoside Rb1 from Panax ginseng , 1998 .
[56] M. Sporn,et al. Recent advances in chemoprevention of cancer. , 1997, Science.
[57] A. Fattaey,et al. Human Myt1 Is a Cell Cycle-regulated Kinase That Inhibits Cdc2 but Not Cdk2 Activity* , 1997, The Journal of Biological Chemistry.
[58] K. Keyomarsi,et al. The role of cyclin E in cell proliferation, development and cancer. , 1997, Progress in cell cycle research.
[59] C. Huggins,et al. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.